Skip to main navigation
Leap therapeutics
Leap therapeutics
  • About
    • About
    • Contact Us
  • Pipeline
    • Pipeline
    • Sirexatamab (DKN-01) Programs
      • Gastric Cancer
      • Colorectal Cancer
      • Endometrial Cancer
      • Prostate Cancer
      • Lung Cancer
    • FL-501 Program
  • Science
    • Science
    • DKK1
    • Sirexatamab (DKN-01)
    • GDF15
  • Patients
    • Patients
    • Expanded Access
  • Careers
  • Investors
    • Investors
    • Stock Information
    • News Releases
    • Presentations & Events
    • Financial Information
    • Corporate Governance
    • Information Request

SEC
Filing

image description

Document Details

Form
S-8
Filing Date
Jun 9, 2026
Document Date
Jun 9, 2026
Form Description
Securities offered to employees pursuant to employee benefit plans
Filing Group
Registration Statements
Company
Leap Therapeutics, Inc.
Issuer
CYPHERPUNK TECHNOLOGIES INC.

Filing Formats

View HTML
Download PDF
Download DOC
Download XLS

XBRL

XBRL Viewer
XML - XBRL INSTANCE DOCUMENT
  • image Print Page Print Page
  • image Email Alerts Email Alerts
  • image Contact Us Contact Us
image description
image description
Leap therapeutics
47 Thorndike Street, Suite B1-1 Cambridge, MA 02141 USA
+1 617 714 0360

Business inquiries
bd@leaptx.com

Investor inquiries
ir@leaptx.com

  • ABOUT
  • CONTACT US
  • CAREERS
  • PIPELINE
  • Sirexatamab (DKN-01) Programs
  • FL-501 Program
  • PATIENTS
  • EXPANDED ACCESS
  • SCIENCE
  • DKK1
  • Sirexatamab (DKN-01)
  • GDF-15
  • INVESTORS
  • STOCK INFORMATION
  • NEWS RELEASES
  • PRESENTATIONS & EVENTS
  • FINANCIAL INFORMATION
  • CORPORATE GOVERNANCE
  • INFORMATION REQUEST
  • © 2026 Leap Therapeutics, Inc.
  • All Rights Reserved.
  • Terms of Use
  • Privacy Policy
  • Cookie Policy